Characterization and optimization of the ReLiver engineered liver tissue****

该项目将在维多利亚大学的Willerth实验室**和位于魁北克的Morphocell Technologies之间启动首次合作。Morphocell Technologies是一家再生医学公司，专注于干细胞疗法和旨在治疗肝病的工程组织的开发和商业化。特别是，该项目将使他们的肝脏产品得到进一步的表征和优化--该产品由来自人诱导多能干细胞(HiPSCs)的功能性肝组织组成，这些细胞被称为有机类化合物。RELISER产品由HiPSC衍生的肝组织组成，包裹在聚乙二醇(PEG)涂层内，促进生物相容性。该项目将使用扫描电子显微镜对涂层的性能进行表征，包括孔径大小，并将研究替代生物材料配方以改善涂层性能。威勒斯博士在生物材料和基于干细胞的组织工程领域有超过15年的经验，使她成为这个项目的合乎逻辑的合作伙伴。

This project will initiate a first time collaboration between the Willerth laboratory at the University of Victoria**and Morphocell Technologies located in Quebec. Morphocell Technologies is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues aimed at treating liver diseases. In particular, this project will enable further characterization and optimization of their ReLiver product - which consists of functional liver tissues derived from human induced pluripotent stem cells (hiPSCs) known as organoids. The ReLiver product consists hiPSC-derived liver tissues encapsulated inside of a poly (ethylene glycol) (PEG) coating that promotes biocomptability. This project will characterize the properties, including pore size, using scanning electron microscopy and will investigate alternative biomaterials formulations to improve the coating properties. Dr. Willerth has over 15 years of experience in the fields of biomaterials and stem cell-based tissue engineering, making her a logical partner for this project.******